Ginkgo Bioworks Holdings, Inc. WT
Ginkgo Bioworks Holdings, Inc. WT DNA-WT Peers
See (DNA-WT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
| VRTX | $445.82 | -0.99% | 114.5B | -116.10 | -$3.84 | N/A |
| REGN | $520.29 | -0.38% | 55.2B | 13.22 | $39.35 | +0.17% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $321.82 | -0.98% | 42B | -152.52 | -$2.11 | N/A |
| ARGX | $560.82 | -1.27% | 34.2B | 34.22 | $16.39 | N/A |
| BNTX | $104.69 | -0.38% | 25.2B | -28.60 | -$3.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.91 | -0.64% | 20.2B | 14.66 | $2.45 | +2.40% |
| SMMT | $21.33 | +1.96% | 15.8B | -62.74 | -$0.34 | N/A |
Stock Comparison
DNA-WT vs VRTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRTX has a market cap of 114.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while VRTX trades at $445.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -116.10. In terms of profitability, DNA-WT's ROE is -0.63%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, DNA-WT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs REGN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, REGN has a market cap of 55.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while REGN trades at $520.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 13.22. In terms of profitability, DNA-WT's ROE is -0.63%, compared to REGN's ROE of +0.15%. Regarding short-term risk, DNA-WT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs SGEN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DNA-WT's ROE is -0.63%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DNA-WT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ALNY Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALNY has a market cap of 42B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALNY trades at $321.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -152.52. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, DNA-WT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ARGX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARGX has a market cap of 34.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while ARGX trades at $560.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 34.22. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, DNA-WT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BNTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BNTX has a market cap of 25.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while BNTX trades at $104.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -28.60. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, DNA-WT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BGNE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, DNA-WT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RPRX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RPRX has a market cap of 20.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while RPRX trades at $35.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 14.66. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, DNA-WT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs SMMT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SMMT has a market cap of 15.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while SMMT trades at $21.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -62.74. In terms of profitability, DNA-WT's ROE is -0.63%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, DNA-WT is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs INCY Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INCY has a market cap of 13.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while INCY trades at $67.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 337.75. In terms of profitability, DNA-WT's ROE is -0.63%, compared to INCY's ROE of +0.01%. Regarding short-term risk, DNA-WT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs UTHR Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, UTHR has a market cap of 12.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while UTHR trades at $285.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 11.40. In terms of profitability, DNA-WT's ROE is -0.63%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DNA-WT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs GMAB Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, GMAB has a market cap of 12.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while GMAB trades at $20.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 12.07. In terms of profitability, DNA-WT's ROE is -0.63%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, DNA-WT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs KRTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DNA-WT's ROE is -0.63%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs EXEL Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while EXEL trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 19.88. In terms of profitability, DNA-WT's ROE is -0.63%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, DNA-WT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ASND Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while ASND trades at $173.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -25.98. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ASND's ROE of +1.91%. Regarding short-term risk, DNA-WT is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MRNA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRNA has a market cap of 10.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while MRNA trades at $26.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -3.08. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, DNA-WT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BMRN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while BMRN trades at $54.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 20.05. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, DNA-WT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RXDX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs IMGN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DNA-WT's ROE is -0.63%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, DNA-WT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BBIO Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BBIO has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while BBIO trades at $44.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -12.47. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, DNA-WT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BPMC Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while BPMC trades at $128.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.31. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, DNA-WT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CERE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CERE's ROE of -0.43%. Regarding short-term risk, DNA-WT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs TECH Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while TECH trades at $51.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 62.52. In terms of profitability, DNA-WT's ROE is -0.63%, compared to TECH's ROE of +0.06%. Regarding short-term risk, DNA-WT is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs VRNA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRNA has a market cap of 8.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while VRNA trades at $95.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -47.55. In terms of profitability, DNA-WT's ROE is -0.63%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, DNA-WT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CORT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while CORT trades at $73.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 64.34. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CORT's ROE of +0.20%. Regarding short-term risk, DNA-WT is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ROIVW Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, DNA-WT is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ROIV Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while ROIV trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -15.20. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, DNA-WT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RVMD Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while RVMD trades at $38.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -9.58. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, DNA-WT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs AMRN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AMRN has a market cap of 6.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while AMRN trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AMRN's P/E ratio is -3.68. In terms of profitability, DNA-WT's ROE is -0.63%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, DNA-WT is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RETA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DNA-WT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs JAZZ Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, JAZZ has a market cap of 6.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while JAZZ trades at $107.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 14.55. In terms of profitability, DNA-WT's ROE is -0.63%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, DNA-WT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs HALO Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, HALO has a market cap of 6.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while HALO trades at $52.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 13.91. In terms of profitability, DNA-WT's ROE is -0.63%, compared to HALO's ROE of +1.22%. Regarding short-term risk, DNA-WT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs IONS Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IONS has a market cap of 6.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while IONS trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -13.38. In terms of profitability, DNA-WT's ROE is -0.63%, compared to IONS's ROE of -0.92%. Regarding short-term risk, DNA-WT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MDGL Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MDGL has a market cap of 6.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while MDGL trades at $277.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -15.57. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, DNA-WT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs TGTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while TGTX trades at $37.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 149.04. In terms of profitability, DNA-WT's ROE is -0.63%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, DNA-WT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs NUVL Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NUVL has a market cap of 5.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while NUVL trades at $79.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -18.35. In terms of profitability, DNA-WT's ROE is -0.63%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ABCM Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DNA-WT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ISEE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DNA-WT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs TLX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while TLX trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 177.67. In terms of profitability, DNA-WT's ROE is -0.63%, compared to TLX's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs AXSM Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while AXSM trades at $103.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -17.96. In terms of profitability, DNA-WT's ROE is -0.63%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, DNA-WT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ALKS Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALKS trades at $28.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 13.76. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, DNA-WT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ALPN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, DNA-WT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs AKRO Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AKRO has a market cap of 4.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while AKRO trades at $55.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.68. In terms of profitability, DNA-WT's ROE is -0.63%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, DNA-WT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs SLNO Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SLNO has a market cap of 4.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while SLNO trades at $85.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -18.10. In terms of profitability, DNA-WT's ROE is -0.63%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, DNA-WT is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs PCVX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while PCVX trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -8.29. In terms of profitability, DNA-WT's ROE is -0.63%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, DNA-WT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ADMA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ADMA has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while ADMA trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 20.96. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, DNA-WT is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs OPT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, DNA-WT's ROE is -0.63%, compared to OPT's ROE of +2.60%. Regarding short-term risk, DNA-WT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs KRYS Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRYS has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while KRYS trades at $142.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 34.17. In terms of profitability, DNA-WT's ROE is -0.63%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MRTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DNA-WT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CRSP Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while CRSP trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -10.61. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, DNA-WT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ZLAB Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ZLAB has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while ZLAB trades at $36.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ZLAB's P/E ratio is -14.78. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, DNA-WT is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MRUS Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRUS has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27, while MRUS trades at $53.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -12.95. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, DNA-WT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RYTM Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27, while RYTM trades at $62.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -22.24. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, DNA-WT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CYTK Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27, while CYTK trades at $33.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -6.26. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, DNA-WT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs PTCT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while PTCT trades at $48.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.51. In terms of profitability, DNA-WT's ROE is -0.63%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, DNA-WT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ACAD Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while ACAD trades at $22.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 16.43. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, DNA-WT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RYZB Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DNA-WT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CBAY Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DNA-WT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RNA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RNA has a market cap of 3.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while RNA trades at $29.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -9.97. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RNA's ROE of -0.27%. Regarding short-term risk, DNA-WT is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs SWTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while SWTX trades at $46.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.77. In terms of profitability, DNA-WT's ROE is -0.63%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, DNA-WT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RARE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while RARE trades at $37.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -6.42. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RARE's ROE of -1.86%. Regarding short-term risk, DNA-WT is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ACLX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACLX has a market cap of 3.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ACLX trades at $64.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -21.43. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, DNA-WT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs AAPG Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while AAPG trades at $39.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -52.80. In terms of profitability, DNA-WT's ROE is -0.63%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, DNA-WT is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs SRRK Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while SRRK trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -14.04. In terms of profitability, DNA-WT's ROE is -0.63%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, DNA-WT is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs PTGX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while PTGX trades at $54.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 69.79. In terms of profitability, DNA-WT's ROE is -0.63%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, DNA-WT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs LEGN Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LEGN has a market cap of 3.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while LEGN trades at $33.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -28.33. In terms of profitability, DNA-WT's ROE is -0.63%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, DNA-WT is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs VKTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, DNA-WT is priced at $0.27, while VKTX trades at $27.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -23.35. In terms of profitability, DNA-WT's ROE is -0.63%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, DNA-WT is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs KYMR Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, DNA-WT is priced at $0.27, while KYMR trades at $46.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -14.93. In terms of profitability, DNA-WT's ROE is -0.63%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, DNA-WT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MLTX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MLTX has a market cap of 3B. Regarding current trading prices, DNA-WT is priced at $0.27, while MLTX trades at $47.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -20.60. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MORF Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MORF's ROE of -0.22%. Regarding short-term risk, DNA-WT is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MOR Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MOR's ROE of +2.51%. Regarding short-term risk, DNA-WT is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CRNX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while CRNX trades at $30.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -8.01. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MTSR Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MTSR has a market cap of 2.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while MTSR trades at $26.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -10.49. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, DNA-WT is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs KDNY Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, DNA-WT's ROE is -0.63%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, DNA-WT is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs IMVT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while IMVT trades at $15.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -5.77. In terms of profitability, DNA-WT's ROE is -0.63%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, DNA-WT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CPRX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while CPRX trades at $21.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 13.72. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, DNA-WT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MYOV Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, DNA-WT is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs APGE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APGE has a market cap of 2.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while APGE trades at $43.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -11.92. In terms of profitability, DNA-WT's ROE is -0.63%, compared to APGE's ROE of -0.19%. Regarding short-term risk, DNA-WT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs MIRM Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while MIRM trades at $50.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -31.14. In terms of profitability, DNA-WT's ROE is -0.63%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, DNA-WT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs XENE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while XENE trades at $31.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -9.86. In terms of profitability, DNA-WT's ROE is -0.63%, compared to XENE's ROE of -0.32%. Regarding short-term risk, DNA-WT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs IBRX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while IBRX trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -4.84. In terms of profitability, DNA-WT's ROE is -0.63%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, DNA-WT is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs PRVB Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, DNA-WT's ROE is -0.63%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, DNA-WT is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs LBPH Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, DNA-WT's ROE is -0.63%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, DNA-WT is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs APLS Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APLS has a market cap of 2.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while APLS trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -10.21. In terms of profitability, DNA-WT's ROE is -0.63%, compared to APLS's ROE of -1.00%. Regarding short-term risk, DNA-WT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs DICE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, DNA-WT's ROE is -0.63%, compared to DICE's ROE of +0.56%. Regarding short-term risk, DNA-WT is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs LGND Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while LGND trades at $115.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -15.90. In terms of profitability, DNA-WT's ROE is -0.63%, compared to LGND's ROE of -0.16%. Regarding short-term risk, DNA-WT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs ARWR Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while ARWR trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -12.63. In terms of profitability, DNA-WT's ROE is -0.63%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, DNA-WT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CALT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CALT's P/E ratio is -22.73. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CALT's ROE of -1.67%. Regarding short-term risk, DNA-WT is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs VCEL Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while VCEL trades at $41.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VCEL's P/E ratio is 837.60. In terms of profitability, DNA-WT's ROE is -0.63%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, DNA-WT is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs DNLI Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while DNLI trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.42. In terms of profitability, DNA-WT's ROE is -0.63%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs VCYT Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while VCYT trades at $26.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 62.98. In terms of profitability, DNA-WT's ROE is -0.63%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, DNA-WT is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs KNSA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while KNSA trades at $28.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is -118.25. In terms of profitability, DNA-WT's ROE is -0.63%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, DNA-WT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs RXRX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RXRX has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while RXRX trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RXRX's P/E ratio is -2.87. In terms of profitability, DNA-WT's ROE is -0.63%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, DNA-WT is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs NAMS Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NAMS has a market cap of 2.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while NAMS trades at $18.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -9.94. In terms of profitability, DNA-WT's ROE is -0.63%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, DNA-WT is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BCRX Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BCRX has a market cap of 2B. Regarding current trading prices, DNA-WT is priced at $0.27, while BCRX trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BCRX's P/E ratio is -37.38. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, DNA-WT is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs CGON Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CGON has a market cap of 2B. Regarding current trading prices, DNA-WT is priced at $0.27, while CGON trades at $26.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -17.41. In terms of profitability, DNA-WT's ROE is -0.63%, compared to CGON's ROE of -0.17%. Regarding short-term risk, DNA-WT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs BLTE Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, DNA-WT is priced at $0.27, while BLTE trades at $60.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -44.78. In terms of profitability, DNA-WT's ROE is -0.63%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs IDYA Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IDYA has a market cap of 1.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while IDYA trades at $22.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IDYA's P/E ratio is -6.03. In terms of profitability, DNA-WT's ROE is -0.63%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, DNA-WT is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.
DNA-WT vs AGIO Comparison
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AGIO has a market cap of 1.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while AGIO trades at $32.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AGIO's P/E ratio is 2.83. In terms of profitability, DNA-WT's ROE is -0.63%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, DNA-WT is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.